Trials / Recruiting
RecruitingNCT06319157
Minimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
A Randomized Controlled Study of Minimal Access Latissimus Dorsi Flap Harvest for Breast Reconstruction Versus Conventional Approaches in the Treatment of Early Breast Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 94 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
For patients refusing implants for breast reconstruction after cancer surgery, autologous tissue flap reconstruction using the latissimus dorsi muscle is an alternative. Conventional surgery leaves a long incision on the back, affecting aesthetics and quality of life. Minimal access techniques result in a smaller, more concealable scar. While previous studies suggest its safety and effectiveness, most are retrospective. To further validate patient satisfaction and short-term outcomes, a prospective, randomized controlled trial comparing minimal access with conventional surgery is planned. The primary endpoint is Breast Q-satisfaction with back score at 6 months. Secondary outcomes include other Breast Q subscales, surgical metrics, and complications. The study aims to enroll 94 patients in total, providing evidence for surgical decision-making in breast cancer reconstruction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | minimal access breast reconstruction with a latissimus dorsi muscle flap | minimal access breast reconstruction with a latissimus dorsi muscle flap |
| DEVICE | conventional breast reconstruction with a latissimus dorsi muscle flap | conventional breast reconstruction with a latissimus dorsi muscle flap |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2028-11-01
- Completion
- 2028-11-01
- First posted
- 2024-03-19
- Last updated
- 2024-03-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06319157. Inclusion in this directory is not an endorsement.